Netherton Syndrome Market Insights report from DelveInsight provides a thorough understanding of the Netherton Syndrome Market size by treatment, epidemiology, emerging therapies, market share of the various therapies, and the current and forecasted Netherton Syndrome Market size from 2019 to 2032 divided into the 7MM (the USA, EU5 (Germany, France, Italy, Spain, and the UK), and Japan) regions.
Netherton Syndrome Overview
Netherton syndrome (NS) is a rare autosomal recessive syndromic ichthyosis caused by mutations of the SPINK5 gene, which encodes the lymphoepithelial Kazal-type-related inhibitor (LEKTI) protein. The exact incidence of NS is unknown, partly because it is difficult to diagnose. With around 150 cases reported in the scientific literature, it is estimated that approximately 1/200,000 people worldwide have NS.
Download Sample Report- https://www.delveinsight.com/sample-request/netherton-syndrome-market
Regions covered in the report
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Key highlights of the Netherton Syndrome Market Report
As per the estimates by DelveInsight, prevalence of mild to moderate cases of Netherton Syndrome is higher than severe cases which are subjected to an increase in the coming years.
As per the National Organization of Rare Disorders (NORD), NS is a rare hereditary disorder with approximately 150 cases reported in the medical literature. However, the actual number of affected individuals may be much higher due to diagnostic difficulties and overlapping symptoms with common atopic dermatitis and other congenital ichthyoses.
In the United States, the severe cases of Netherton Syndrome were estimated to be about 184 cases in 2021 which are expected to rise during the study period 2019–2032.
Netherton Syndrome Epidemiology Insights
The incidence and prevalence of NS have been estimated to be 1/200,000 births and 1–9/million, respectively; similar numbers are published in most of the literature available worldwide. Moreover, it has been reported that that NS could account for up to 18% of congenital erythroderma.
Netherton Syndrome Epidemiology Segmentation in the 7MM
Netherton syndrome prevalent cases
Netherton syndrome Severity-specific Cases
Do you want to know more information related to report? If yes, visit here- https://www.delveinsight.com/sample-request/netherton-syndrome-market
Netherton Syndrome Market Insights
There is an urgent need for a targeted, effective and well-tolerated therapy. Kallikrein inhibitors represent a new potential therapy for NS. Kallikrein inhibition is typically absent in NS and thus, the inhibitor properties of this treatment may prevent or minimize the inflammatory cutaneous features that are generally present. One of the emerging molecule, LM-030 (previously known as BPR277), now licensed to LifeMax, has been granted Fast Track Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation by the FDA for topical treatment of NS. It is an inhibitor of kallikrein-related peptidase 7 (KLK7) and epidermal elastase 2 (ELA2), targets the underlying cause of NS, and is well-positioned to become the first approved treatment for this debilitating and potentially life-threatening disease.
Netherton Syndrome Therapeutics Market
There is no curative or specific therapy targeting NS pathophysiology and NS treatment is mostly palliative. The therapeutic strategies for NS can be classified into two broad categories:
Therapies aiming to restore the skin barrier
Therapies aim to suppress/modulate the immune response, allergy, and skin infections and thus decrease skin/systemic features.
Netherton Syndrome market size in the 7MM was USD XXXX million in 2021. The market size shall increase during the forecast period (2019–2032), owing to the launch of upcoming therapies.
Netherton Syndrome Emerging Therapy Assessment
There is no approved treatment for Netherton Syndrome. Current approaches are all limited to symptom relief or supportive care with marginal efficacy and undesirable side effects. There is an urgent need for a targeted, effective and well-tolerated therapy.
Netherton Syndrome Market Dynamics
Netherton Syndrome market dynamics is anticipated to change in the coming years owing to the improvement in the research and development undertaking. There are several key players involved in developing the therapies for Netherton Syndrome like LifeMax Laboratories, AnaptysBio and Janssen Biotech. The launch of emerging therapies is expected during the forecast period of 2022-2032.
Request Sample Report- https://www.delveinsight.com/sample-request/netherton-syndrome-market
Table of Content
1. Key Insights
2. Netherton Syndrome Executive Summary
3. Competitive Intelligence Analysis for Netherton Syndrome
4. Netherton Syndrome: Market Overview at a Glance
5. Netherton Syndrome: Disease Background and Overview
6. Netherton Syndrome Patient Journey
7. Netherton Syndrome Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Netherton Syndrome Unmet Needs
10. Key Endpoints of Netherton Syndrome Treatment
11. Netherton Syndrome Marketed Products
12. Netherton Syndrome Emerging Therapies
13. Netherton Syndrome: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Netherton Syndrome Market Outlook
16. Access and Reimbursement Overview of Netherton Syndrome
17. KOL Views
18. Netherton Syndrome Market Drivers
19. Netherton Syndrome Market Barriers
21. DelveInsight Capabilities
23. About DelveInsight
Netherton Syndrome Market Report Scope
In the coming years, the Netherton Syndrome market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Netherton Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing therapies for Netherton Syndrome. The launch of emerging therapies will significantly impact the Netherton Syndrome market
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Netherton Syndrome
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Why should you buy this report?
The report will help in developing business strategies by understanding trends shaping and driving the Netherton Syndrome market
To understand the future market competition in the Netherton Syndrome market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Netherton Syndrome in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Netherton Syndrome market
To understand the future market competition in the Netherton Syndrome market
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States